FDA approved high-concentration, citrate-free formulation of Cyltezo® injection
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), the company’s interchangeable biosimilar to Humira® (adalimumab), to treat multiple chronic inflammatory diseases. “With this FDA approval, we are now able…